18 February 2023>: Clinical Research
Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
Tomislav Jukic 1CDEF , David Drobne 2ABCDE , Sasa Pusavec 3BF , Alojz Ihan 3AE , David Stubljar 4ACDE* , Andrej Starc 5DEDOI: 10.12659/MSM.939084
Med Sci Monit 2023; 29:e939084
Table 5 Comparison of antibodies to IFX concentrations between University of Leuven (UHL) and Lisa Tracker.
Patient ID | TL IFX (μg/mL) – UHL | ATI (μg/mL) – UHL | ATI (μg/mL) – Lisa-Tracker |
---|---|---|---|
19 | 15.7 | 2.33 | |
20 | >20.0 | Excess | |
21 | 8.03 | 2.19 | |
22 | >20.0 | Excess | |
23 | 14.4 | 1.80 | |
24 | 15.7 | 2.92 | |
25 | 0.0352 | ||
26 | 1.30 | 0.384 | |
27 | 7.57 | 1.16 | |
28 | 0.0796 | ||
29 | 2.47 | 0.655 | |
30 | 0.88 | 0.0477 | |
31 | 0.67 | 0.00 | |
32 | 0.98 | 0.00 |